作者
Ana Maria Valencia‐Hernandez,Wei Yi Ng,Nazanin Ghazanfari,Sonia Ghilas,María Menezes,Lauren E. Holz,Cheng Huang,Kieran English,Myo Naung,Peter Tan,Kirsteen M. Tullett,Thiago M. Steiner,Matthias H. Enders,Lynette Beattie,Yu Cheng Chua,Claerwen M. Jones,Anton Cozijnsen,Vanessa Mollard,Yeping Cai,David G. Bowen,Anthony W. Purcell,Nicole L. La Gruta,José A. Villadangos,Tania F. de Koning‐Ward,Peter Siba,Winfried Barchet,Ian A. Cockburn,Geoffrey I. McFadden,Stéphanie Gras,Mireille H. Lahoud,Patrick Bertolino,Ralf B. Schittenhelm,Irina Caminschi,William R. Heath,Daniel Fernandez‐Ruiz
摘要
Liver-resident memory CD8+ T (TRM) cells remain in and constantly patrol the liver to elicit rapid immunity upon antigen encounter and can mediate efficient protection against liver-stage Plasmodium infection. This finding has prompted the development of immunization strategies where T cells are activated in the spleen and then trapped in the liver to form TRM cells. Here, we identify PbRPL6120-127, a H2-Kb-restricted epitope from the putative 60S ribosomal protein L6 (RPL6) of Plasmodium berghei ANKA, as an optimal antigen for endogenous liver TRM cell generation and protection against malaria. A single dose vaccination targeting RPL6 provided effective and prolonged sterilizing immunity against high dose sporozoite challenges. Expressed throughout the parasite life cycle, across Plasmodium species, and highly conserved, RPL6 exhibits strong translation potential as a vaccine candidate. This is further advocated by the identification of a broadly conserved, immunogenic HLA-A∗02:01-restricted epitope in P. falciparum RPL6.